HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC

Clinical trial NCT06632093 · RECRUITING

Trial details

NCT number: NCT06632093
Sponsor: First Hospital of China Medical University
Status: RECRUITING
Study type: OBSERVATIONAL

BCLC Stage B Hepatocellular Carcinoma BCLC Stage C Hepatocellular Carcinoma Hepatic Arterial Infusion Chemotherapy Lenvatinib PD-1 Systemic Therapy

Start date: 2024-09-16
Primary completion: 2025-09-30
Enrollment: 84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.